The Journal of thoracic and cardiovascular surgery · 2026
Neoadjuvant chemoradiation versus perioperative chemotherapy in locally advanced resectable esophageal adenocarcinoma: A national analysis.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sakowitz Sara, Bakhtiyar Syed Shahyan, Sanaiha Yas, Kronen Elsa, Benharash Peyman, Yanagawa Jane
Аннотация
OBJECTIVE: There is ongoing debate regarding the optimal multimodal treatment for patients with resectable locally advanced esophageal adenocarcinoma, with the recent ESOPEC trial suggesting perioperative chemotherapy to yield superior survival compared with Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study (CROSS) neoadjuvant chemoradiation. Providing a contemporary perspective, we sought to elucidate survival outcomes among a national cohort.
METHODS: We performed a retrospective analysis of all clinically staged T1N+M0 or T2-4aN±M0 esophageal adenocarcinoma patients ≥18 years within the 2016-2023 National Cancer Database. Only patients who underwent esophagectomy were considered. Those who received neoadjuvant chemotherapy and ≥41.4 Gy radiation were grouped as Neoadjuvant-CR, whereas patients treated with perioperative multi-agent chemotherapy were considered Perioperative-Chemo.
RESULTS: Of 7387 patients who underwent esophagectomy, 462 (6%) received Perioperative-Chemo and 6925 (94%) Neoadjuvant-CR. On average, and relative to Neoadjuvant-CR, the Perioperative-Chemo was incrementally younger, but of similar sex, CDI, and mean tumor size. Overall survival at 5 years was 49% for Perioperative-Chemo and 42% for Neoadjuvant-CR. After risk adjustment, and relative to receipt of neoadjuvant chemoradiation, treatment with perioperative chemotherapy was linked with improved survival at 1 (hazard ratio [HR], 0.66; 95% CI, 0.48-0.90), 3 (HR, 0.76; CI, 0.62-0.93), and 5 years (HR, 0.80; CI, 0.66-0.97). Restricted mean survival time analysis was used to quantify the survival benefit of perioperative chemotherapy at 3.7 months (CI, 0.01-7.5 months).
CONCLUSIONS: Among patients who underwent esophagectomy, treatment with perioperative chemotherapy was linked with superior survival over 5 years, relative to neoadjuvant chemoradiotherapy. Our work supports the early findings of the ESOPEC trial and suggests perioperative chemotherapy should be considered upfront in the multimodal treatment of these complex patients.
METHODS: We performed a retrospective analysis of all clinically staged T1N+M0 or T2-4aN±M0 esophageal adenocarcinoma patients ≥18 years within the 2016-2023 National Cancer Database. Only patients who underwent esophagectomy were considered. Those who received neoadjuvant chemotherapy and ≥41.4 Gy radiation were grouped as Neoadjuvant-CR, whereas patients treated with perioperative multi-agent chemotherapy were considered Perioperative-Chemo.
RESULTS: Of 7387 patients who underwent esophagectomy, 462 (6%) received Perioperative-Chemo and 6925 (94%) Neoadjuvant-CR. On average, and relative to Neoadjuvant-CR, the Perioperative-Chemo was incrementally younger, but of similar sex, CDI, and mean tumor size. Overall survival at 5 years was 49% for Perioperative-Chemo and 42% for Neoadjuvant-CR. After risk adjustment, and relative to receipt of neoadjuvant chemoradiation, treatment with perioperative chemotherapy was linked with improved survival at 1 (hazard ratio [HR], 0.66; 95% CI, 0.48-0.90), 3 (HR, 0.76; CI, 0.62-0.93), and 5 years (HR, 0.80; CI, 0.66-0.97). Restricted mean survival time analysis was used to quantify the survival benefit of perioperative chemotherapy at 3.7 months (CI, 0.01-7.5 months).
CONCLUSIONS: Among patients who underwent esophagectomy, treatment with perioperative chemotherapy was linked with superior survival over 5 years, relative to neoadjuvant chemoradiotherapy. Our work supports the early findings of the ESOPEC trial and suggests perioperative chemotherapy should be considered upfront in the multimodal treatment of these complex patients.